8-K: Invivyd Secures FDA Emergency Use Authorization for PEMGARDA, a COVID-19 Pre-Exposure Prophylaxis

Invivyd's PEMGARDA, a monoclonal antibody, has received FDA emergency use authorization for pre-exposure prophylaxis of COVID-19 in certain immunocompromised individuals, marking a significant milestone for the company.

Summary

• Invivyd has received Emergency Use Authorization (EUA) from the FDA for PEMGARDA (formerly VYD222), a monoclonal antibody for pre-exposure prophylaxis (PrEP) of COVID-19 in adults and adolescents with moderate-to-severe immune compromise.
• The EUA is based on immunobridging data from the CANOPY clinical trial, which showed that PEMGARDA's neutralizing antibody titers against the JN.1 variant were consistent with levels associated with efficacy in previous trials.
• PEMGARDA is the first monoclonal antibody to receive EUA based on a rapid immunobridging trial design, which is expected to be repeatable for future antibody development.
• The company estimates it had $200.6 million in cash and cash equivalents as of December 31, 2023, and raised an additional $40.5 million in February 2024 through an at-the-market offering.
• Invivyd expects its current cash reserves to fund operations into the fourth quarter of 2024, excluding anticipated revenue from PEMGARDA sales.
• Interim data from the CANOPY trial showed a potential early signal of clinical protection from symptomatic COVID-19, with a low rate of confirmed cases in both the immunocompromised and non-immunocompromised cohorts.

Sentiment

Score: 8

Explanation: The document is highly positive due to the FDA authorization, strong cash position, and promising clinical data. However, there are some risks and safety concerns that temper the overall sentiment.

Positives

• The FDA's EUA for PEMGARDA marks a significant milestone for Invivyd and its technology platform.
• The rapid immunobridging trial design allows for faster development of new monoclonal antibodies.
• The company has a strong cash position to support the launch of PEMGARDA and ongoing operations.
• Interim data from the CANOPY trial suggest a potential for clinical protection against symptomatic COVID-19.
• PEMGARDA has demonstrated in vitro neutralizing activity against major SARS-CoV-2 variants, including JN.1.

Negatives

• Anaphylaxis was observed in a small percentage of participants, requiring careful monitoring during and after infusion.
• The safety data showed a higher rate of hypersensitivity reactions in the open-label cohort with immunocompromised participants.
• The estimated cash balance is preliminary and subject to change upon completion of the audited financial statements.
• The company's cash runway is projected to extend only into the fourth quarter of 2024, excluding potential revenue from PEMGARDA sales.

Risks

• The EUA for PEMGARDA could be revoked or revised by the FDA.
• The company may face challenges in building and maintaining sales, marketing, and distribution capabilities.
• There is a risk of competition from other therapies.
• Unexpected safety or efficacy data could emerge during clinical trials.
• The company relies on third parties for manufacturing, testing, and distribution.
• The company may not be able to provide sufficient commercial supply of PEMGARDA to meet market demand.
• The company may not be able to obtain and maintain third-party coverage and adequate reimbursement for PEMGARDA.
• New SARS-CoV-2 variants may emerge that are not neutralized by PEMGARDA.
• The company's ability to continue as a going concern is dependent on securing additional funding.

Future Outlook

Invivyd expects its existing cash to fund operations into the fourth quarter of 2024, excluding potential revenue from PEMGARDA sales, and plans to explore the protective clinical benefits of mAb prophylaxis for symptomatic COVID-19 in future studies. The company also plans to share launch metrics in coming quarters.

Management Comments

• Dave Hering, Chief Executive Officer, stated that the EUA milestone represents strategic proof-of-concept for the company and its platform.
• Mr. Hering also mentioned the company's commitment to ongoing process improvement and working with global regulatory agencies to increase the speed and efficiency of new mAb candidate development.
• Mr. Hering noted that the company is planning to explore the protective clinical benefits of mAb prophylaxis for symptomatic COVID-19 disease in future studies.

Industry Context

This announcement comes at a time when there is a need for effective preventative measures against COVID-19, particularly for immunocompromised individuals. The authorization of PEMGARDA fills a gap left by the loss of activity of previous monoclonal antibody treatments, such as Evusheld, and represents a significant step forward in the development of antibody-based therapies for viral threats.

Comparison to Industry Standards

• The immunobridging approach used for PEMGARDA is a novel and rapid method compared to traditional clinical trials, potentially accelerating the development of new monoclonal antibodies.
• The company's approach is designed to address the challenge of rapid viral evolution, which is a key concern in the development of effective COVID-19 therapies.
• The company is aiming to improve on the profile of PEMGARDA with future product candidates, which is consistent with the industry's focus on continuous innovation.
• The company is targeting a specific population of approximately 485,000 immunocompromised individuals in the U.S., which is a significant market opportunity.
• The company is aiming to secure broad coverage from Medicare and commercial payors, which is essential for the successful commercialization of PEMGARDA.
• The company is planning to engage with key account managers to target the 1,150 U.S. institutions that care for the majority of the target population, which is a common strategy in the pharmaceutical industry.

Stakeholder Impact

• Shareholders will benefit from the FDA authorization and potential revenue from PEMGARDA sales.
• Immunocompromised patients will have a new option for COVID-19 prevention.
• Healthcare providers will have a new tool to protect their vulnerable patients.
• Employees will be involved in the launch and commercialization of PEMGARDA.
• Payors will need to determine coverage and reimbursement for PEMGARDA.

Next Steps

• The company plans to launch PEMGARDA imminently.
• The company will engage with key payors to secure broad coverage.
• The company plans to share launch metrics in coming quarters.
• The company will continue to analyze data from the CANOPY trial.
• The company will explore the protective clinical benefits of mAb prophylaxis for symptomatic COVID-19 in future studies.
• The company will continue to develop new monoclonal antibody candidates using its INVYMAB platform.

Key Dates

Keywords

PEMGARDA, COVID-19, monoclonal antibody, pre-exposure prophylaxis, immunocompromised, FDA, Emergency Use Authorization, immunobridging, CANOPY trial, VYD222, INVYMAB, SARS-CoV-2, JN.1